BI-4020 is a 4th-generation, potent, orally bioactive, and non-covalent EGFR tyrosine kinase inhibitor with IC50 of 0.6 nM. It was discovered based on the benzimidazole core structure followed by complete rigidification of the molecule through macrocyclization. BI-4020 potently inhibits the above described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.

纯度：≥98%